OverviewSuggest Edit

NGM Biopharmaceuticals is a drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the Company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. It focuses on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.
TypePublic
Founded2007
HQSouth San Francisco, US
Websitengmbio.com
Employee Ratings3.6

Locations

NGM Biopharmaceuticals is headquartered in
South San Francisco, United States

Location Map

Latest Updates

Employees (est.) (Jan 2019)167
Job Openings30
Revenue (FY, 2018)$108.7 M(+41%)
Share Price (Oct 2019)$10.9 (+6%)

Key People/Management at NGM Biopharmaceuticals

William J. Rieflin

William J. Rieflin

CEO
Luis Bayol

Luis Bayol

CFO
Alex DePaoli

Alex DePaoli

Vice President, Clinical Research
Jin-Long Chen

Jin-Long Chen

Founder, President and Chief Scientific Officer
Chuck Olson

Chuck Olson

Vice President CMC and Technical Operations
Marc Learned

Marc Learned

Executive Director, Research Operations
Show more

NGM Biopharmaceuticals Office Locations

NGM Biopharmaceuticals has an office in South San Francisco
South San Francisco, US (HQ)
333 Oyster Point Blvd
Show all (1)

NGM Biopharmaceuticals Financials and Metrics

NGM Biopharmaceuticals Revenue

NGM Biopharmaceuticals's revenue was reported to be $108.67 m in FY, 2018 which is a 40.9% increase from the previous period.
USD

Revenue (FY, 2018)

108.7m

Revenue growth (FY, 2017 - FY, 2018), %

40.9%

Net income (FY, 2018)

(493.0k)

EBIT (FY, 2018)

(4.3m)

Market capitalization (17-Oct-2019)

717.9m

Closing stock price (17-Oct-2019)

10.9

Cash (31-Dec-2018)

56.9m
NGM Biopharmaceuticals's current market capitalization is $717.9 m.
USDFY, 2017FY, 2018

Revenue

77.1m108.7m

Revenue growth, %

41%

General and administrative expense

14.8m17.3m

R&D expense

79.7m95.7m
USDFY, 2017FY, 2018

Cash

25.6m56.9m

Prepaid Expenses

1.8m4.3m

Current Assets

175.5m214.6m

PP&E

24.9m23.9m
USDFY, 2017FY, 2018

Net Income

(14.2m)(493.0k)

Depreciation and Amortization

6.4m7.2m

Accounts Payable

(4.2m)3.5m

Cash From Operating Activities

(17.4m)(7.6m)
USDY, 2018

Financial Leverage

-2.3 x
Show all financial metrics

NGM Biopharmaceuticals Online and Social Media Presence

Embed Graph

NGM Biopharmaceuticals Frequently Asked Questions

  • When was NGM Biopharmaceuticals founded?

    NGM Biopharmaceuticals was founded in 2007.

  • Who are NGM Biopharmaceuticals key executives?

    NGM Biopharmaceuticals's key executives are William J. Rieflin, Luis Bayol and Alex DePaoli.

  • How many employees does NGM Biopharmaceuticals have?

    NGM Biopharmaceuticals has 167 employees.

  • What is NGM Biopharmaceuticals revenue?

    Latest NGM Biopharmaceuticals annual revenue is $108.7 m.

  • What is NGM Biopharmaceuticals revenue per employee?

    Latest NGM Biopharmaceuticals revenue per employee is $650.7 k.

  • Who are NGM Biopharmaceuticals competitors?

    Competitors of NGM Biopharmaceuticals include Scynexis, vTv Therapeutics and Lixte Biotechnology.

  • Where is NGM Biopharmaceuticals headquarters?

    NGM Biopharmaceuticals headquarters is located at 333 Oyster Point Blvd, South San Francisco.

  • Where are NGM Biopharmaceuticals offices?

    NGM Biopharmaceuticals has an office in South San Francisco.

  • How many offices does NGM Biopharmaceuticals have?

    NGM Biopharmaceuticals has 1 office.